Navigation Links
Hop, skip or jump? Study says no to all of the above
Date:4/17/2013

CAMBRIDGE, MA -- Osteoarthritis, which affects at least 20 percent of adults in the United States, leads to deterioration of cartilage, the rubbery tissue that prevents bones from rubbing together. By studying the molecular properties of cartilage, MIT engineers have now discovered how the earliest stages of arthritis make the tissue more susceptible to damage from physical activities such as running or jumping.

The findings could help researchers develop tests to diagnose arthritis earlier in patients at high risk for the disease and also guide engineers in designing replacement cartilage. The results also suggest that athletes who suffer traumatic knee injuries, such as a torn anterior cruciate ligament (ACL) which gives them a greater chance of developing arthritis later in life should be cautious when returning to their sport following surgery.

"It's a clear signal to be careful of going right back out," says Alan Grodzinsky, an MIT professor of biological, electrical and mechanical engineering and senior author of a paper describing the findings in a recent issue of the Biophysical Journal. "Even though your knee may be stabilized, there's the possibility that deformation of cartilage at a high loading rate is still going to put it at risk."

Cartilage is packed with protein-sugar complexes known as aggrecans, each made of about 100 highly charged molecules called glycosaminoglycans (GAGs). Those molecules protect joints by absorbing water and causing the tissue to stiffen as pressure is applied.

"The cartilage is a stiff sponge, filled with fluid, and as we compress it, fluid has to percolate through these closely spaced GAG chains," Grodzinsky says. "The GAG chains provide resistance to flow, so the water can't get out of our cartilage instantly when we compress it. That pressurization at the nanoscale increases the stiffness of our cartilage to high-loading-rate activities."

The MIT team set out to in
'/>"/>

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Federal Government Organization achieves cleaner and faster Clinical Study Data using Tablet PCs from TabletKiosk
2. Half of Tamiflu prescriptions went unused during 2009 H1N1 swine flu pandemic, UK sewage study
3. CU-Boulder study looks at microbial differences between parents, kids and dogs
4. TGen-led study discovers dramatic changes in bacteria following male circumcision
5. Mount Sinai study identifies new gene variations associated with heart rate
6. Study proposes alternative way to explain lifes complexity
7. Exercise or make dinner? Study finds adults trade one healthy act for another
8. BUSM researchers identify novel approach to study COPD and treatment efficacy
9. Sustainable fishing certification too lenient and discretionary, study finds
10. Methane emissions from natural gas local distribution focus of new study
11. Short daily walk might help teen smokers cut down or quit, new study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
(Date:7/24/2014)... its own microbial terroir, meaning the microbial populations found ... the product, creating the final flavor according to research ... and Environmental Microbiology . This is the first time ... brewery. , Many sake makers inoculate with both ... of the University of California, Davis, but he and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... 2010) -- Drug delivery inside the body is a ... solutions, lipid membranes, and barriers between the blood and ... Institute of Physics publication the Journal of Chemical ... the hydration free energy (HFE) of a wide variety ...
... (July 27, 2010) -- In biology and genetics, the concept ... more (or less) than the sum of its parts. The ... an organism has the potential to depend strongly upon the ... even other mutations co-occurring in that gene. These genetic interactions, ...
... punch tiny holes in the protective membranes of cells, ... small molecules, proteins and DNA directly into living cells. ... light trigger the tiny blasts, which open holes in ... contained in the surrounding fluid. By adjusting laser ...
Cached Biology News:Getting a step ahead of pathogens 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 3Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 4
(Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 WIRB-Copernicus Group ® ... ethical review services for clinical research, announced today ... division of Richmond, VA -based ... and biosecurity consulting firm in the ... biosafety division – WCG Biosafety™ – will be ...
(Date:7/24/2014)... 24, 2014   Cypher Genomics, Inc., ... of Adam Simpson as president and ... and comprehensive annotation and interpretation of individual human ... "Cypher,s technology has the potential to play ... diagnostic accuracy, optimizing therapeutic approaches and reducing adverse ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... Submission for Removal of Clinical Hold, BERKELEY ... Board: GNTA) announced that the Company has,received notice ... European,Patent Office for its pipeline product, tesetaxel, a ... matter for the tesetaxel drug,substance and to processes ...
... prion reduction technology to, further reduce risk of variant ... ... Octaplas(R), - Octapharma sponsoring lunchtime Symposium at meeting to discuss ... product quality., MONTREAL, Canada and CAMBRIDGE, United Kingdom, June 10,/PRNewswire-FirstCall/ ...
... Targets, COPENHAGEN, June 10 Nuevolution A/S ... (Nasdaq: LXRX ) aimed,at the discovery of ... targets., Under the terms of the alliance, ... to identify novel small molecule,lead compounds against a ...
Cached Biology Technology:Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 2Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 3
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Biology Products: